Year: 2020

Amarin Decision Update: To Europe and Beyond
December 10, 2020 Blog Post Snowfish

As the world waits for COVID-19 vaccines to become widely available, Amarin experiences a different form of anticipation, one which will see the fate of its own profitability. Our previous blog post on Amarin highlighted the disastrous effects of a U.S Court of Appeals decision to invalidate Amarin’s six patents. To briefly recap, while the

Advanced Practice Providers: A Forgotten Market Segment
November 5, 2020 Blog Post Snowfish

Image from the StarTribune. After heading into a clinic and filling out the required forms, the assistant calls you back. “Wait in room number two,” the assistant says. Once there, a medical assistant enters and takes your vitals, leaving you with the confidence a qualified person will see you soon. A short while later,

The Rush for a COVID-19 Vaccine – The Ramifications
October 8, 2020 Blog Post Snowfish

Image from Newsday. With everyone is rushing to return pre-pandemic society, it is becoming clear that a vaccine is the only way to truly get there. Anxiously, the world waits on a vaccine for COVID-19 to get us back to work, back to school, back to play, and back to basic human connection. In

Update: Pharmaceutical Mergers and Acquisitions: Will They Drive Growth?
September 17, 2020 Blog Post Snowfish

Mergers and acquisitions are a hot topic in the biopharmaceutical industry. With 2019 setting records in terms of deal value and volume for biopharmaceutical M&A, many question the purpose of these processes. In addition to increasing shareholder value, management pursues mergers and acquisitions for a variety of reasons including innovation, synergy, and portfolio realignment. In

Amarin Decision: A Tragic Loss for Life Science and Patients
September 7, 2020 Blog Post Snowfish

In a relatively quick ruling, one that Amarin expected to occur in Q4 at the earliest, the U.S Court of Appeals for the Federal Circuit in Washington invalidated Amarin’s six patents. Essentially, this upheld the decision by the U.S District Court for the District of Nevada that Amarin’s patents for Vascepa, were a variation of

Competition vs Innovation: US Legislation Impacting Pharma in the 2020’s
August 25, 2020 Blog Post Snowfish

Time is ticking! Need to optimize the value of a new therapy before generics are available. How can we extend the patent? These are all top of mind when developing, commercializing and managing the life cycle of a therapy. Unless engaged heavily in government affairs, it is easy to miss that this is all guided

The Montreal Cognitive Assessment: Not an Intelligence Test
August 7, 2020 Blog Post Snowfish

In a recent interview with Fox News host Chris Wallace, US President Donald Trump discussed his success taking the Montreal Cognitive Assessment (MoCA). The President appeared quite proud to have achieved a perfect score. He then questioned whether Wallace himself could answer the last five questions on the exam noting their difficulty. I was instantly

Precision medicine and companion diagnostics: The “Incredible” future of disease management
July 21, 2020 Blog Post Snowfish

We all know one size never fits all, yet, for the vast majority of medical history, care providers have been using that approach. Fortunately, with the advances in molecular and genetic medicine, precision medicine has become a viable alternative to the outdated and inefficient one-size-fits-all approach. Precision medicine, as the name suggests, does not concern

How KOLs use social media
June 30, 2020 Blog Post Snowfish

Many debates have been held on the merits of social media. When it comes to the health care industry, the terms “key opinion leaders (KOLs)” and “Twitter” tend not to belong in the same sentence. Understandably as historically, health care practitioners in general have tended to be laggers not leaders, when it comes to technology

Trauma centers save lives… unequally
June 18, 2020 Blog Post Snowfish

Often the sites of harrowing injuries, trauma centers are a vital part of the U.S healthcare system. Trauma centers save lives. According to the New England Journal of Medicine, victims treated at trauma centers have a 25% higher survival rate when compared with treatment at non-trauma hospitals. The simple assertion that trauma centers save lives